Sood AK - Search Results

1

Targeting CCR2⁺ macrophages with BET inhibitor overcomes adaptive resistance to anti-VEGF therapy in ovarian cancer.

Wu Y, Jennings NB, Sun Y, Dasari SK, Bayraktar E, Corvigno S, Stur E, Glassman D, Mangala LS, Lankenau Ahumada A, Westin SN, Sood AK, Hu W. Wu Y, et al. Among authors: sood ak. J Cancer Res Clin Oncol. 2022 Apr;148(4):803-821. doi: 10.1007/s00432-021-03885-z. Epub 2022 Jan 30. J Cancer Res Clin Oncol. 2022. PMID: 35094142 Free PMC article.

2

The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy.

Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JE, Seftor EA, Hendrix MJ. Sood AK, et al. Cancer Biol Ther. 2002 Nov-Dec;1(6):661-4. doi: 10.4161/cbt.316. Cancer Biol Ther. 2002. PMID: 12642690 Free article.

3

EphA2 expression is associated with aggressive features in ovarian carcinoma.

Thaker PH, Deavers M, Celestino J, Thornton A, Fletcher MS, Landen CN, Kinch MS, Kiener PA, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2004 Aug 1;10(15):5145-50. doi: 10.1158/1078-0432.CCR-03-0589. Clin Cancer Res. 2004. PMID: 15297418

4

Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum-resistant ovarian carcinoma: results of a phase II trial.

Sood AK, Lush R, Geisler JP, Shahin MS, Sanders L, Sullivan D, Buller RE, Sorosky JI. Sood AK, et al. Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6080-5. doi: 10.1158/1078-0432.CCR-04-0574. Clin Cancer Res. 2004. PMID: 15447993 Clinical Trial.

5

Fifth International Conference on Ovarian Cancer: challenges and opportunities.

Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Sood AK, et al. Gynecol Oncol. 2005 Jun;97(3):916-23. doi: 10.1016/j.ygyno.2005.03.013. Gynecol Oncol. 2005. PMID: 15907981

6

Inhibition of experimental colon cancer metastasis by the GABA-receptor agonist nembutal.

Thaker PH, Yokoi K, Jennings NB, Li Y, Rebhun RB, Rousseau DL Jr, Fan D, Sood AK. Thaker PH, et al. Among authors: sood ak. Cancer Biol Ther. 2005 Jul;4(7):753-8. doi: 10.4161/cbt.4.7.1827. Epub 2005 Jul 9. Cancer Biol Ther. 2005. PMID: 15970706 Free article.

7

Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors.

Thaker PH, Yazici S, Nilsson MB, Yokoi K, Tsan RZ, He J, Kim SJ, Fidler IJ, Sood AK. Thaker PH, et al. Among authors: sood ak. Clin Cancer Res. 2005 Jul 1;11(13):4923-33. doi: 10.1158/1078-0432.CCR-04-2060. Clin Cancer Res. 2005. PMID: 16000591

8

Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.

Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK. Landen CN Jr, et al. Among authors: sood ak. Cancer Res. 2005 Aug 1;65(15):6910-8. doi: 10.1158/0008-5472.CAN-05-0530. Cancer Res. 2005. PMID: 16061675

9

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.

Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Hu L, et al. Among authors: sood ak. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71. doi: 10.1158/1078-0432.CCR-05-0910. Clin Cancer Res. 2005. PMID: 16203789

10

EphA2 as a target for ovarian cancer therapy.

Landen CN, Kinch MS, Sood AK. Landen CN, et al. Among authors: sood ak. Expert Opin Ther Targets. 2005 Dec;9(6):1179-87. doi: 10.1517/14728222.9.6.1179. Expert Opin Ther Targets. 2005. PMID: 16300469 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,163 results

Search Page

Filters